|Day Low/High||3.76 / 4.10|
|52 Wk Low/High||2.15 / 5.78|
Vivus was a leading decliner within the health care sector, falling $0.39 (-3.0%) to $12.48 on average volume
First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.
Data From Successful Placebo-Controlled Study to be Submitted to Regulatory Authorities to Support STENDRA Label Amendment for 15-Minute Efficacy Claim
First Manhattan Co., the beneficial owner of approximately 9.
In trading on Thursday, shares of Vivus, Inc. crossed above their 200 day moving average of $14.90, changing hands as high as $15.04 per share.
Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.